GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

The costs will be funded through existing resources. There are no changes to GSK's growth agenda or investment plans for R&D as a result of these settlements.' Zantac was approved in 1983 and ...

Additionally, GSK has reached an agreement in principle to pay a total of $70 million to settle a Zantac qui tam complaint ... reductions in future legal costs. The costs of these settlements ...

The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits ... get this monkey off its back almost regardless of the cost”. Earlier estimates by Morgan Stanley suggested the ...